INTRAVESICAL RESINIFERATOXIN FOR THE TREATMENT OF INTERSTITIAL CYSTITIS: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL

In the largest prospective, randomized clinical trial reported to date with intravesical vanilloid therapy, single administration of RTX at doses of 0.01 μM to 0.10 μM was not effective in patients with interstitial cystitis.